MX2020009288A - Metodos y composiciones de los profarmacos isoindolina-1,3-diona e isoindol utiles para el tratamiento del cancer, colitis ulcerosa y enfermedades inflamatorias relacionadas. - Google Patents
Metodos y composiciones de los profarmacos isoindolina-1,3-diona e isoindol utiles para el tratamiento del cancer, colitis ulcerosa y enfermedades inflamatorias relacionadas.Info
- Publication number
- MX2020009288A MX2020009288A MX2020009288A MX2020009288A MX2020009288A MX 2020009288 A MX2020009288 A MX 2020009288A MX 2020009288 A MX2020009288 A MX 2020009288A MX 2020009288 A MX2020009288 A MX 2020009288A MX 2020009288 A MX2020009288 A MX 2020009288A
- Authority
- MX
- Mexico
- Prior art keywords
- isoindoline
- isoindole
- dione
- compositions
- methods
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 4
- 239000000651 prodrug Substances 0.000 title abstract 4
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 title 1
- 206010009900 Colitis ulcerative Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000006704 Ulcerative Colitis Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical group C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 title 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000002518 isoindoles Chemical class 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639650P | 2018-03-07 | 2018-03-07 | |
| PCT/EP2019/055576 WO2019170750A1 (en) | 2018-03-07 | 2019-03-06 | Methods and compositions of isoindoline-1,3-dione and isoindole prodrugs useful for treating cancer, ulcerative colitis and related inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009288A true MX2020009288A (es) | 2020-09-28 |
Family
ID=65894963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009288A MX2020009288A (es) | 2018-03-07 | 2019-03-06 | Metodos y composiciones de los profarmacos isoindolina-1,3-diona e isoindol utiles para el tratamiento del cancer, colitis ulcerosa y enfermedades inflamatorias relacionadas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11639332B2 (https=) |
| EP (1) | EP3762365B1 (https=) |
| JP (1) | JP7396991B2 (https=) |
| AR (1) | AR114666A1 (https=) |
| AU (1) | AU2019229583B2 (https=) |
| CA (1) | CA3093196A1 (https=) |
| ES (1) | ES2987705T3 (https=) |
| MA (1) | MA52266A (https=) |
| MX (1) | MX2020009288A (https=) |
| TW (1) | TW202000646A (https=) |
| WO (1) | WO2019170750A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118370746A (zh) * | 2024-04-25 | 2024-07-23 | 江苏省中医院 | 马尿酸在制备溃疡性结肠炎治疗药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2472965A (en) | 1949-06-14 | Metallized tetrakisazo dyes | ||
| US3951943A (en) | 1974-03-18 | 1976-04-20 | Chemetron Corporation | Coupling process in the preparation of disazo diimides |
| EP0856562A1 (en) | 1997-01-31 | 1998-08-05 | Hodogaya Chemical Co Ltd | Recording liquid and novel metal complex compound contained therein |
| US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| JPWO2002001667A1 (ja) * | 2000-06-29 | 2004-01-08 | 日本化薬株式会社 | 色素増感光電変換素子 |
| US7842662B2 (en) * | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| AU2008270363A1 (en) * | 2007-06-29 | 2009-01-08 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Targeting diazo prodrugs for the treatment of gastrointestinal diseases |
| CA2718601A1 (en) | 2008-03-27 | 2009-10-01 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| WO2012083153A1 (en) * | 2010-12-16 | 2012-06-21 | Nektar Therapeutics | Oligomer-containing apremilast moiety compounds |
| MX347928B (es) | 2011-01-10 | 2017-05-19 | Celgene Corp | Derivados de fenetilsulfona isoindolina y su uso. |
-
2019
- 2019-03-06 WO PCT/EP2019/055576 patent/WO2019170750A1/en not_active Ceased
- 2019-03-06 JP JP2020547036A patent/JP7396991B2/ja active Active
- 2019-03-06 US US16/970,598 patent/US11639332B2/en active Active
- 2019-03-06 CA CA3093196A patent/CA3093196A1/en active Pending
- 2019-03-06 MX MX2020009288A patent/MX2020009288A/es unknown
- 2019-03-06 TW TW108107510A patent/TW202000646A/zh unknown
- 2019-03-06 ES ES19712695T patent/ES2987705T3/es active Active
- 2019-03-06 MA MA052266A patent/MA52266A/fr unknown
- 2019-03-06 AU AU2019229583A patent/AU2019229583B2/en active Active
- 2019-03-06 EP EP19712695.6A patent/EP3762365B1/en active Active
- 2019-03-06 AR ARP190100547A patent/AR114666A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR114666A1 (es) | 2020-09-30 |
| AU2019229583A1 (en) | 2020-09-10 |
| MA52266A (fr) | 2021-01-13 |
| CA3093196A1 (en) | 2019-09-12 |
| EP3762365A1 (en) | 2021-01-13 |
| TW202000646A (zh) | 2020-01-01 |
| JP7396991B2 (ja) | 2023-12-12 |
| ES2987705T3 (es) | 2024-11-15 |
| AU2019229583B2 (en) | 2024-06-13 |
| JP2021517134A (ja) | 2021-07-15 |
| US20200392082A1 (en) | 2020-12-17 |
| US11639332B2 (en) | 2023-05-02 |
| WO2019170750A1 (en) | 2019-09-12 |
| EP3762365B1 (en) | 2024-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002919A1 (es) | Inhibidores de mcl-1 | |
| MX2021013788A (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres. | |
| CO2019001212A2 (es) | Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| MY196173A (en) | Cot Modulators And Methods Of Use Thereof | |
| CL2019000819A1 (es) | Compuestos y composiciones para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
| CL2017001124A1 (es) | Agentes inmunomoduladores | |
| MX2016011063A (es) | Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica. | |
| CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2018001996A1 (es) | Composiciones y métodos para modular la expresión del factor b del complemento (divisional de solicitud 2764-16) | |
| MX2016016993A (es) | Compuestos de heteroarilo utiles como inhibidores de enzima activadora de sumo. | |
| CL2018000955A1 (es) | Terapia de combinación para el tratamiento de neoplasias malignas | |
| AR104387A1 (es) | Composiciones detergentes | |
| PA8846801A1 (es) | Composiciones farmacéuticas que contienen diacereína | |
| MX2016001901A (es) | Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno. | |
| MX2017007973A (es) | Tratamiento de penfigo. | |
| CO2021008816A2 (es) | Moduladores de trex1 | |
| MX2022012146A (es) | Combinaciones para el tratamiento de neoplasias utilizando localizacion de celulas quiescentes e inhibidores de la mitosis. | |
| CL2021002847A1 (es) | Terapias de combinación que comprenden inhibidores de apremilast y tyk2 | |
| CL2018000927A1 (es) | Terapia combinada para el tratamiento de neoplasias malignas | |
| NZ714662A (en) | Extended-release formulation for reducing the frequency of urination and method of use thereof | |
| NZ711754A (en) | Pharmaceutical compositions for the treatment of helicobacter pylori | |
| MX2021000154A (es) | Metodos de tratamiento de fibrosis hepatica que usan inhibidores de calpaina. | |
| MA41116B1 (fr) | Compositions sélectives d'inhibiteur il-6-trans-signalisation | |
| CR20220280A (es) | Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2 |